What Comes After Ozempic? - The Amylin Gambit: Novo's Bet on a Forgotten Hormone

from What Comes After Ozempic? Next-Gen Weight Loss Drugs · host Inception Point AI

Ben Synth explores how Novo Nordisk is betting on amylin, a long-overlooked hormone, to create the next generation of obesity drugs. From CagriSema's 20% weight loss to amycretin's stunning 24% in just 36 weeks, these dual-action therapies could dethrone semaglutide by targeting appetite through complementary brain pathways—rewriting the obesity treatment playbook. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Episode metadata supplied by the publisher feed · Published Apr 7, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

What Comes After Ozempic? - The Amylin Gambit: Novo's Bet on a Forgotten Hormone

0:00 28:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of What Comes After Ozempic? Next-Gen Weight Loss Drugs?

This episode is 28 minutes long.

When was this What Comes After Ozempic? Next-Gen Weight Loss Drugs episode published?

This episode was published on April 7, 2026.

Can I download this What Comes After Ozempic? Next-Gen Weight Loss Drugs episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!